CN110234769B - 表观遗传染色体相互作用在癌症诊断中的应用 - Google Patents
表观遗传染色体相互作用在癌症诊断中的应用 Download PDFInfo
- Publication number
- CN110234769B CN110234769B CN201780085308.2A CN201780085308A CN110234769B CN 110234769 B CN110234769 B CN 110234769B CN 201780085308 A CN201780085308 A CN 201780085308A CN 110234769 B CN110234769 B CN 110234769B
- Authority
- CN
- China
- Prior art keywords
- dna
- interactions
- chromosomal
- sequence
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| US62/428,893 | 2016-12-01 | ||
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110234769A CN110234769A (zh) | 2019-09-13 |
| CN110234769B true CN110234769B (zh) | 2024-06-07 |
Family
ID=60702831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780085308.2A Active CN110234769B (zh) | 2016-12-01 | 2017-11-30 | 表观遗传染色体相互作用在癌症诊断中的应用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (enExample) |
| EP (2) | EP4357463A3 (enExample) |
| JP (2) | JP2019535295A (enExample) |
| KR (1) | KR102481242B1 (enExample) |
| CN (1) | CN110234769B (enExample) |
| AU (1) | AU2017367245B2 (enExample) |
| CA (1) | CA3045070A1 (enExample) |
| ES (1) | ES2971286T3 (enExample) |
| MY (1) | MY190153A (enExample) |
| PL (1) | PL3548633T3 (enExample) |
| TW (1) | TWI865427B (enExample) |
| WO (1) | WO2018100381A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225551A1 (en) * | 2019-05-08 | 2020-11-12 | Oxford BioDynamics PLC | Chromosome conformation markers of prostate cancer and lymphoma |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036323A1 (en) * | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
| CN102046813A (zh) * | 2008-06-02 | 2011-05-04 | 牛津生物动力有限公司 | 检测远距离染色体相互作用的方法 |
| WO2012159025A2 (en) * | 2011-05-18 | 2012-11-22 | Life Technologies Corporation | Chromosome conformation analysis |
| CN102827935A (zh) * | 2012-08-29 | 2012-12-19 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| CN103547598A (zh) * | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564262A (en) * | 2005-07-04 | 2010-02-26 | Univ Erasmus Medical Ct | Chromosome conformation capture-on-chip (4C) assay |
| GB0603251D0 (en) * | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| AU2008204338B2 (en) * | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
| CA2609172A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Utah Research Foundation | Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| EP2366162A1 (en) * | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
| CA2804450C (en) * | 2010-07-09 | 2022-10-11 | Max Jan van Min | 3-d genomic region of interest sequencing strategies |
| AU2013280644B2 (en) * | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| JP2018518203A (ja) | 2015-06-24 | 2018-07-12 | オックスフォード バイオダイナミックス リミテッド | エピジェネティックな染色体相互作用 |
| EP3390656B1 (en) * | 2015-12-14 | 2020-04-08 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102046813A (zh) * | 2008-06-02 | 2011-05-04 | 牛津生物动力有限公司 | 检测远距离染色体相互作用的方法 |
| WO2010036323A1 (en) * | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
| CN103547598A (zh) * | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
| WO2012159025A2 (en) * | 2011-05-18 | 2012-11-22 | Life Technologies Corporation | Chromosome conformation analysis |
| CN102827935A (zh) * | 2012-08-29 | 2012-12-19 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
Non-Patent Citations (2)
| Title |
|---|
| 6例髓系肉瘤的临床病理分析;姜青明等;临床肿瘤学杂志;20150415;第20卷(第4期);351-356 * |
| Insulator dysfunction and oncogene activation in IDH mutant gliomas;William A. Flavahan等，;《nature》;20151223;第110–114页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018100381A1 (en) | 2018-06-07 |
| CA3045070A1 (en) | 2018-06-07 |
| TW201842190A (zh) | 2018-12-01 |
| ES2971286T3 (es) | 2024-06-04 |
| TWI865427B (zh) | 2024-12-11 |
| NZ753716A (en) | 2024-05-31 |
| MY190153A (en) | 2022-03-31 |
| KR20190086569A (ko) | 2019-07-22 |
| US11560597B2 (en) | 2023-01-24 |
| KR102481242B1 (ko) | 2022-12-23 |
| AU2017367245B2 (en) | 2020-09-24 |
| EP3548633B1 (en) | 2024-01-24 |
| PL3548633T3 (pl) | 2024-04-02 |
| JP2023027076A (ja) | 2023-03-01 |
| US20230082230A1 (en) | 2023-03-16 |
| EP4357463A3 (en) | 2024-07-17 |
| EP3548633A1 (en) | 2019-10-09 |
| EP3548633C0 (en) | 2024-01-24 |
| JP7579003B2 (ja) | 2024-11-07 |
| AU2017367245A1 (en) | 2019-06-06 |
| CN110234769A (zh) | 2019-09-13 |
| EP4357463A2 (en) | 2024-04-24 |
| US20190338367A1 (en) | 2019-11-07 |
| JP2019535295A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102622307B1 (ko) | 후성유전적 염색체 상호작용 | |
| CN109661477B (zh) | 与乳腺癌相关的染色体相互作用的检测 | |
| JP7631400B2 (ja) | 遺伝子調節 | |
| JP7579003B2 (ja) | がんの診断における後成的染色体相互作用の応用 | |
| AU2018344573A1 (en) | Biomarker | |
| US11535893B2 (en) | Typing method | |
| HK40111334A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| CN116507740A (zh) | 检测作为用于纤维化例如硬皮病的标志物的染色体构象 | |
| JP2022548249A (ja) | 診断用染色体マーカー | |
| HK40013967A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| HK40013967B (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| KR20240006020A (ko) | 염색체 상호작용 마커 | |
| CN117203350A (zh) | 染色体相互作用 | |
| HK40076364A (en) | Diagnostic chromosome marker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Ushizu Applicant after: Oxford biodynamics Ltd. Address before: Ushizu Applicant before: OXFORD BIODYNAMICS Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |